Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Milton Packer(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Faı̈ez Zannad(Inserm), Martina Brueckmann, Javed Butler(University of Mississippi Medical Center), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(University of London), Hans‐Peter Brunner‐La Rocca(Inserm), Stefan Janssens(Inserm), Janet Schnee(Boehringer Ingelheim (United States)), Hiroyuki Tsutsui(Kyushu University), Jian Zhang(Texas A&M Health Science Center), João Pedro Ferreira(Inserm), Stefan D. Anker, Tomoko Iwata(Boehringer Ingelheim (Germany)), Daniel Cotton(Boehringer Ingelheim (Germany)), Waheed Jamal(Inserm)
Cited by 135
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k